NIH and partners to start HIV vaccine trial in Europe and America
Category: #health  By Sunil Hebbalkar  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

NIH and partners to start HIV vaccine trial in Europe and America
  • A unit of Janssen Pharmaceutical Companies of Johnson & Johnson would be sponsoring the Mosaico trial.
  • A complementary study involving women is also currently under process in southern Africa.

The National Institutes of Health (NIH), a biomedical research unit of the U.S. Department of Health and Human Services, and its partners recently announced their plans to commence a Phase 3 clinical trial that would test the efficacy of an investigational HIV vaccine.

Reports cite, the trial would take place across a number or clinical research sites, including Europe, South America and North America. The proposed trial has been dubbed Mosaico or HPX3002/HVTN 706 and is set to launch soon.

According to reports, Janssen Vaccines & Prevention, B.V., a unit of Janssen Pharmaceutical Companies of Johnson & Johnson, would be sponsoring the Mosaico trial. The study would enroll 3,800 HIV negative transgenders and men that are sexually active with other transgenders or/and men. Along with the U.S., other countries such as Italy, Mexico, Poland, Peru, Argentina, Spain and Brazil would also be participating in the study.

The Director of NIAID Anthony S. Fauci, M.D., stated that the organization is committed towards the creation of an effective and safe HIV vaccine that would help people that are most vulnerable to HIV across globe. Dr. Fauci further added that ensuring evaluation of such investigational vaccines among a diverse demographic is crucial for attaining the goal.

All trial participants would be offered a complete HIV prevention package and would be randomly assigned either the investigational HIV vaccine or placebo. The investigational vaccines would be administered at four separate time points over a years’ worth of time.

According to reports, the Mosaico trial would be the third HIV vaccine efficacy clinical study in progress across the world. The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) would be providing funding support to the clinical trial which is expected to be open for enrollment in the U.S. by the end of the year.

Source Credits: https://www.nih.gov/news-events/news-releases/nih-partners-launch-hiv-vaccine-efficacy-trial-americas-europe



About Author

Sunil Hebbalkar

Email: [email protected]   

Sunil Hebbalkar

Sunil Hebbalkar develops content for Algosonline, Market Size Forecasters, and a couple of other platforms. A Post graduate mechanical design engineer by qualification, he worked as an intern at the defense lab for one year in the engine design and development departm...

Read More

More News By Sunil Hebbalkar

Altaire’s veterinary ophthalmic products recalled due to QA concerns
Altaire’s veterinary ophthalmic products recalled due to QA concerns
By Sunil Hebbalkar

  • Altaire Pharmaceuticals recalls specific product/lots of ophthalmic drugs created for Dechra Veterinary Products, due to sterility concerns.
     
  • No adverse effects have been reported yet.
Biogen & Invitae introduce SMA STAT test for faster genetic testing
Biogen & Invitae introduce SMA STAT test for faster genetic testing
By Sunil Hebbalkar

Global biotechnology expert Biogen Inc. and advanced genetics leader Invitae Corporation have reportedly announced their new rapid-turnaround test for genetic testing in the diagnosis for SMA (spinal muscular atrophy)....

Target launches flagship food label with more than 2000 products
Target launches flagship food label with more than 2000 products
By Sunil Hebbalkar

US based retailer Target has reportedly announced the launch of its new private grocery brand, Good & Gather.

Starting next month, Target stores across the United States will st...